MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Innovent Biologics Inc (OP:IVBXF)

10.09 -0.15 (-1.43%)
Streaming Delayed Price Updated: 12:42 PM EDT, Jun 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 794
Open 10.09
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 10.24
Today's Range 9.776 - 10.09
52wk Range 9.260 - 15.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Can Pfizer's Dividend Survive the Patent Cliff? This $10.5 Billion Cancer Bet Could Hold the Answer. ↗
The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal ↗
Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... 
Via Talk Markets

Performance

YTD
-6.7%
-6.7%
1 Month
-2.0%
-2.0%
3 Month
-3.9%
-3.9%
6 Month
-9.6%
-9.6%
1 Year
+9.0%
+9.0%

More News

Read More
News headline image
Week In Review: Nanjing Triastek Partners With BioNTech In A $1.2 Billion Drug Development Deal ↗
Via Talk Markets
News headline image
Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma ↗
Via Talk Markets
News headline image
Week In Review: Fosun Pharma Plans $690 Million Deal To Privatize Henlius, Its Biologics Subsidiary ↗
Via Talk Markets
News headline image
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings ↗
Via Talk Markets
News headline image
Week In Review: Sciwind, Sino Biological And Biocytogen Announce Deals ↗
Via Talk Markets
News headline image
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion ↗
Via Talk Markets
News headline image
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities ↗
Via Talk Markets
News headline image
Week In Review: EurekaBio Raises $40 Million To Support Lentiviral Vector Platform ↗
Via Talk Markets
News headline image
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal ↗
Via Talk Markets
News headline image
Week In Review: AlphaGen And ArtBio Form China-US Radioligand Partnership ↗
Via Talk Markets
News headline image
Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million ↗
Via Talk Markets
News headline image
Week In Review: $1.7 Billion Collaboration Between Elpiscience And Astellas Is Final 2023 Deal ↗
Via Talk Markets
News headline image
Week In Review: Tang Capital Offers $465 Million For LianBio Plus 80% Of Any Licenses/Divestments ↗
Via Talk Markets
News headline image
Week In Review: Hengrui Out-Licenses Next-Gen PARP1 To Merck KGaA For $1.7 Billion ↗
Via Talk Markets
News headline image
Week In Review: A Consortium Of China Drug Distributors Want To Acquire Poland's Neuca ↗
Via Talk Markets
News headline image
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration ↗
Via Talk Markets
News headline image
Week In Review: CMBG Out-Licenses Two CAR-T Candidates To Janssen For $245 Million Upfront ↗
Via Talk Markets
News headline image
Week In Review: Cullgen Signs $1.9 Billion Protein Degrader Deal With Astellas ↗
Via Talk Markets
News headline image
Week In Review: Shanghai HighTide Therapeutics Files For Hong Kong IPO ↗
Via Talk Markets
News headline image
Week In Review: BlissBio Announces Potential $2 Billion Deal With Eisai For HER2 ADC ↗
Via Talk Markets
News headline image
Week In Review: China Biopharmas Announce Three Out-Licensing Deals Totaling $2 Billion ↗
Via Talk Markets
News headline image
Week In Review: Structure Stages $161 Million US IPO For AI/Structure-Based Drug Development ↗
Via Talk Markets
News headline image
Week In Review: Boston Scientific Pays $523 Million For Majority Stake In Beijing Acotec Scientific ↗
Via Talk Markets

Frequently Asked Questions

Is Innovent Biologics Inc publicly traded?
Yes, Innovent Biologics Inc is publicly traded.
What exchange does Innovent Biologics Inc trade on?
Innovent Biologics Inc trades on the OTC Traded
What is the ticker symbol for Innovent Biologics Inc?
The ticker symbol for Innovent Biologics Inc is IVBXF on the OTC Traded
What is the current price of Innovent Biologics Inc?
The current price of Innovent Biologics Inc is 10.09
When was Innovent Biologics Inc last traded?
The last trade of Innovent Biologics Inc was at 06/05/26 12:42 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story